To fully exploit the potential of the new technology, the developed methods needed to be further developed into clinical applications. For this purpose, Nemo Healthcare was founded. With the help of two STW valorization grants, the technology for monitoring uterine activity was developed into a clinically applicable device (PUREtrace™). In 2011, a consortium of investors entered the company, providing the necessary funds for certification and commercialization of PUREtrace. At the same time, we started with the development of technology for measuring fetal heart activity. With a second investment round in 2016 and a EU Horizon 2020 SME (Small and Medium Sized Enterprises) Instrument phase 2 Grant, we are now finishing the development of our fetal monitoring technology, planned to be commercially available in the 2nd half of 2018.